Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.

Kristian Reich,Frank O Nestle,Kim Papp,Jean-Paul Ortonne,Robert Evans,Cynthia Guzzo,Shu Li,Lisa T Dooley,Christopher E M Griffiths

Lancet (London, England)（2005）

引用 1095|浏览25

暂无评分

摘要

Infliximab is effective in both an induction and maintenance regimen for the treatment of moderate-to-severe psoriasis, with a high percentage of patients achieving sustained PASI 75 and PASI 90 improvement through 1 year.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要